Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Axatilimab

Review the clinical trials studying axatilimab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-8 of 8

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Status: Active
Location: 14 locations
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Status: Active
Location: 8 locations
Axatilimab and Olaparib for the Treatment of Patients with BRCA 1/2 and PALB2-Associated Metastatic HER2 Negative Breast Cancer
Status: Active
Location: 3 locations
Axatilimab for the Treatment of Sclerotic Chronic Graft-versus-Host Disease
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Axatilimab and Extracorporeal Photopheresis for the Treatment of Patients with Chronic Graft-versus-Host Disease
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Axatilimab in Combination with Retifanlimab and Paclitaxel for the Treatment of Patients with Advanced or Metastatic Solid Tumors
Status: Active
Location: OHSU Knight Cancer Institute, Portland, Oregon
Axatilimab in Combination with Nivolumab for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Temporarily Closed to Accrual
Location: 2 locations